In the preclinical assessments, we demonstrated that CD19‐CAR‐DNTs inhibited tumor growth in a dose‐dependent manner via a single intravenous administration in the B‐NHL xenograft model; multiple administrations further augment the antitumor effect. Here, CD19 is linked to neoplasm.